Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025

Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis

Read more at globenewswire.com